Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + venetoclax with or without obinutuzumab versus chemoimmunotherapy in untreated CLL
2018-002443-28Phase 3Recruiting
- Sponsor
- Acerta Pharma
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free survival. Started Jan 2019; status: recruiting.
02
Drugs
acalabrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-002443-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002443-28.